C-ABL-IN-2

• Description:

  C-ABL-IN-2 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) [1]. c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• UNSPSC:

  12352005

• Target:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/c-abl-in-2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NC1=CN(C(C)C)C=N1)C2=CC=C(C)C(C#CC3=CC=CN=C3)=C2

• Molecular Formula:

  C21H20N4O

• Molecular Weight:

  344.41

• References & Citations:

  [1] Rebecca PAUL, et al. New compounds and methods. Patent WO2020260871A1.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2574593-54-5]